HCPCS Level II code J2791 denotes a 100 IU dose of rho(d) immune globulin (human), marketed as Rhophylac, administered intramuscularly or intravenously. This code is used for therapeutic or prophylactic administration to provide passive anti-Rh(D) antibodies and has national relevance for obstetric care, post-exposure prevention, and certain transfusion-related indications. Accurate coding of J2791 affects claims processing, inventory tracking, and clinical documentation for biologic immunoglobulin products.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise breakdown of what J2791 represents clinically and operationally, typical sites of service, and the contexts in which the code is billed. The publication outlines common billing considerations and benchmarks where available, highlights recent policy updates that affect coverage and prior authorization practices, and provides clinical context relevant to obstetrics and transfusion medicine. Where input data were not provided, the document notes that specific fields are not available. This summary is written for a national audience and focuses on coding, payer scope, and operational implications rather than state-specific policy.